Effects of Zofenopril on Arterial Stiffness in Hypertension Patients

Palić, Benjamin; Brizić, Ivica; Sher, Emina Karahmet; Cvetković, Ivona; Džidić-Krivić, Amina; Abdelghani, Heba Taha Mohmmed; Sher, Farooq

doi:10.1007/s12033-023-00861-5

Cited by 2 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, type 2 diabetic nephropathy achieved no additional benefits from captopril. It has been discovered that zofenopril, another ACEI with the sulphydryl group (captopril), effectively reduced arterial stiffness compared to enalapril [ 131 ]. Zofenopril was confirmed to increase the availability of NO and reduce endothelin-1 production [ 132 ].…”

Section: Targeting Mechanisms and Recent Advances In The Therapy Of Dkdmentioning

confidence: 99%

Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression

Wang,

Zhang

2024

IJMS

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is a major cause of chronic kidney disease (CKD), and it heightens the risk of cardiovascular incidents. The pathogenesis of DKD is thought to involve hemodynamic, inflammatory, and metabolic factors that converge on the fibrotic pathway. Genetic predisposition and unhealthy lifestyle practices both play a significant role in the development and progression of DKD. In spite of the recent emergence of angiotensin receptors blockers (ARBs)/angiotensin converting enzyme inhibitor (ACEI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and nonsteroidal mineralocorticoid receptors antagonists (NS-MRAs), current therapies still fail to effectively arrest the progression of DKD. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), a promising class of agents, possess the potential to act as renal protectors, effectively slowing the progression of DKD. Other agents, including pentoxifylline (PTF), selonsertib, and baricitinib hold great promise as potential therapies for DKD due to their anti-inflammatory and antifibrotic properties. Multidisciplinary treatment, encompassing lifestyle modifications and drug therapy, can effectively decelerate the progression of DKD. Based on the treatment of heart failure, it is recommended to use multiple drugs in combination rather than a single-use drug for the treatment of DKD. Unearthing the mechanisms underlying DKD is urgent to optimize the management of DKD. Inflammatory and fibrotic factors (including IL-1, MCP-1, MMP-9, CTGF, TNF-a and TGF-β1), along with lncRNAs, not only serve as diagnostic biomarkers, but also hold promise as therapeutic targets. In this review, we delve into the potential mechanisms and the current therapies of DKD. We also explore the additional value of combing these therapies to develop novel treatment strategies. Drawing from the current understanding of DKD pathogenesis, we propose HIF inhibitors, AGE inhibitors, and epigenetic modifications as promising therapeutic targets for the future.

show abstract

Section: Targeting Mechanisms and Recent Advances In The Therapy Of Dkdmentioning

confidence: 99%

Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression

Wang,

Zhang

2024

IJMS

View full text Add to dashboard Cite

show abstract

Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis

Faverio,

Maloberti,

Rebora

et al. 2024

High Blood Press Cardiovasc Prev

View full text Add to dashboard Cite

Introduction Prevalence of cardiac and vascular fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF) has not been extensively evaluated. Aim In this study, we aimed to evaluate the heart and vessels functional and structural properties in patients with IPF compared to healthy controls. An exploratory analysis regarding disease severity in IPF patients has been done. Methods We enrolled 50 patients with IPF (at disease diagnosis before antifibrotic therapy initiation) and 50 controls matched for age and gender. Heart was evaluated through echocardiography and plasmatic NT-pro-brain natriuretic peptide that, together with patients’ symptoms, allow to define the presence of Heart Failure (HF) and diastolic dysfunction. Vessels were evaluated through Flow Mediated Dilation (FMD – endothelial function) and Pulse Wave Velocity (PWV—arterial stiffness) Results Patients with IPF had a prevalence of diastolic disfunction of 83.8%, HF of 37.8% and vascular fibrosis of 76.6%. No statistically significant difference was observed in comparison to the control group who showed prevalence of diastolic disfunction, HF and vascular fibrosis of 67.3%, 24.5% and 84.8%, respectively. Disease severity seems not to affect PWV, FMD, diastolic dysfunction and HF. Conclusions Patients with IPF early in the disease course do not present a significant CV fibrotic involvement when compared with age- and sex-matched controls. Bigger and adequately powered studies are needed to confirm our preliminary data and longitudinal studies are required in order to understand the time of appearance and progression rate of heart and vascular involvement in IPF subjects. Supplementary Information The online version contains supplementary material available at 10.1007/s40292-024-00638-0.

show abstract

Effects of Zofenopril on Arterial Stiffness in Hypertension Patients

Cited by 2 publications

References 68 publications

Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression

Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression

Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis

Contact Info

Product

Resources

About